Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697941 | 0.93 | MEN1 (0.44) | MEN1KMT2AMAPTF2RXFP1 | |
| SCHEMBL6702944 | 0.89 | MEN1 (0.44) | MEN1KMT2AMAPTF2RXFP1 | |
| SCHEMBL6699653 | 0.88 | MEN1 (0.41) | MEN1KMT2AMAPTF2RXFP1 | |
| SCHEMBL6681896 | 0.87 | MEN1 (0.41) | MEN1KMT2AMAPTF2RXFP1 | |
| SCHEMBL6702942 | 0.81 | MEN1 (0.45) | MEN1KMT2AMAPTF2RXFP1 | |
| SCHEMBL6699650 | 0.81 | MEN1 (0.42) | MEN1KMT2AMAPTF2RXFP1 | |
| SCHEMBL6202868 | 0.80 | NR3C1 (0.34) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL6197922 | 0.79 | NR3C1 (0.35) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL6701229 | 0.78 | MAPT (0.48) | MEN1KMT2AMAPTF2RXFP1 | |
| SCHEMBL6693517 | 0.76 | MEN1 (0.42) | MEN1KMT2AMAPTF2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | claimed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | claimed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | disclosed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | MEN1 3030/4885KMT2A 4688/4885MAPT 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.